Alaska Communications has completed important network upgrades extending the life of one of Alaska’s critical communication ...

Moderately bullish activity in Pfizer (PFE), with shares up 32c, or 1.3%, near $25.39. Options volume relatively light with 20k contracts traded ...

Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future ...

Pfizer is advancing research and building a comprehensive "toolbox" for Vietnamese patients, combining innovative vaccines, ...

Pfizer’s investigational drug for sickle cell disease failed in a critical Phase III trial. The company announced that the ...

O’Reilly Auto Parts will become the title sponsor for NASCAR’s second-tier national series when the Xfinity Series is renamed ...

Pfizer Inc. just got a price target bump from Citi. Following a robust Q2, Citi upgraded Pfizer's price target from $25 to ...

Following the company’s strong Q2 performance, Citi raised its price target on Pfizer Inc. (NYSE:PFE) from $25 to $26 on ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...